Lenalidomide (Revlimid) — Clinical FAQs

Question 1

What is Lenalidomide FDA-approved to treat?

Accepted Answer

Lenalidomide is FDA-approved for the following oncology indications: 1. Multiple myeloma — newly diagnosed (with bortezomib and dexamethasone; maintenance after ASCT); relapsed/refractory (with dexamethasone) 2. Myelodysplastic syndrome (MDS) — transfusion-dependent anemia due to deletion 5q (del(5q)) with or without additional cytogenetic abnormalities 3. Mantle cell lymphoma — relapsed/refractory after bortezomib 4. Follicular lymphoma / Marginal zone lymphoma — relapsed/refractory (with rituximab).

Question 2

How does Lenalidomide work (mechanism of action)?

Accepted Answer

Thalidomide analog (immunomodulatory imide drug, IMiD). Binds cereblon (CRBN), a component of the CRL4-CRBN E3 ubiquitin ligase complex. CRBN binding redirects the ubiquitin ligase to degrade transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which are essential for myeloma cell survival and pro-survival cytokine production. Also inhibits TNF-α, stimulates T-cell and NK-cell activity, and has anti-angiogenic properties.

Question 3

How is Lenalidomide administered?

Accepted Answer

Lenalidomide is administered Oral (PO). ONLY available through restricted REMS program (Revlimid REMS).

Question 4

What are the most common side effects of Lenalidomide?

Accepted Answer

The most commonly reported side effects of Lenalidomide (≥10% incidence) include: Myelosuppression (neutropenia, thrombocytopenia), DVT/PE, Fatigue, Constipation and/or diarrhea, Muscle cramps and others (7 total). Consult your oncologist for complete prescribing information.

Question 5

Does Lenalidomide have a black box warning?

Accepted Answer

Yes. Lenalidomide carries FDA black box warning(s) regarding: 1. Embryo-fetal toxicity: thalidomide analog — causes severe birth defects and fetal death. REMS program (Revlimid REMS) with mandatory pregnancy testing and contraception required. 2. Hematologic toxicity: neutropenia and thrombocytopenia — dose reductions required. 3. Venous and arterial thromboembolism: DVT, PE, and MI; antithrombotic prophylaxis required (aspirin, LMWH, or warfarin depending on risk). 4. Increased mortality in CLL: not approved for CLL — clinical trials showed increased early deaths.

Question 6

Is Lenalidomide safe during pregnancy?

Accepted Answer

Lenalidomide pregnancy safety: Category X — Absolutely contraindicated in pregnancy.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Lenalidomide — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms